TSS
VIRX

Two Sigma Securities’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Two Sigma Securities’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16,491
Closed -$2.65K – 2384
2024
Q4 		$2.65K Buy
+16,491
New +$3.25K ﹤0.01% 1497
2024
Q1 		– Sell
-15,634
Closed -$8.91K – 3791
2023
Q4 		$8.91K Buy
+15,634
New +$9.6K ﹤0.01% 2833
2018
Q4 		– Sell
-454
Closed -$32K – 2946
2018
Q3 		$32K Buy
+454
New +$34.5K ﹤0.01% 2393
2016
Q3 		– Sell
-100
Closed -$12K – 811
2016
Q2 		$12K Buy
+100
New +$11.1K 0.01% 397
2016
Q1 		– Sell
-58
Closed -$11K – 419
2015
Q4 		$11K Sell
58
-77
-57% -$14.4K 0.01% 224
2015
Q3 		$23K Buy
+135
New +$48.7K 0.04% 177

Other funds holding VIRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Two Sigma Securities's VIRX Position: Q1 2025 in Review

Two Sigma Securities sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 16,491 shares — an estimated $2.65K sold.

Two Sigma Securities first reported a position in VIRX in Q3 2015 and held it in 6 quarters. The position peaked at $32K in Q3 2018. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • Two Sigma Securities reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Two Sigma Securities sold 16,491 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $2.65K.
  • Two Sigma Securities first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2015 and held it in 6 quarters.
  • Two Sigma Securities's Viracta Therapeutics, Inc. Common Stock position peaked at $32K in Q3 2018.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Two Sigma Securities's 13F filing for Q1 2025, filed 15 May 2025.